Contraceptives

Contraceptives

Global Contraceptives Market to Reach US$39.3 Billion by 2030

The global market for Contraceptives estimated at US$25.7 Billion in the year 2023, is expected to reach US$39.3 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2023-2030. Contraceptive Drugs, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$26.0 Billion by the end of the analysis period. Growth in the Contraceptive Devices segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.7 Billion While China is Forecast to Grow at 9.7% CAGR

The Contraceptives market in the U.S. is estimated at US$6.7 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$9.4 Billion by the year 2030 trailing a CAGR of 9.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Contraceptives Market - Key Trends and Drivers Summarized

Contraceptives are medical products designed to prevent pregnancy by interfering with the normal process of ovulation, fertilization, or implantation. They come in various forms, including oral pills, condoms, intrauterine devices (IUDs), implants, injectables, patches, and emergency contraception pills. Each method offers different levels of effectiveness, durations of action, and suitability based on individual health profiles and preferences. The contraceptive market is driven by several key factors. One significant driver is the increasing awareness and education regarding sexual health and family planning. As governments and non-governmental organizations (NGOs) invest in public health campaigns and educational programs, more individuals are informed about the benefits and availability of contraceptives. This heightened awareness leads to higher adoption rates as people seek to take control of their reproductive health. Additionally, the growing support from various governments in the form of favorable policies and subsidies makes contraceptives more accessible and affordable, further boosting market growth.

The landscape of contraception is constantly evolving with the development of new methods and the extension of existing ones. There is a rising demand for long-acting reversible contraceptives (LARCs) such as IUDs and implants. These methods are becoming increasingly popular due to their high efficacy, convenience, and longer duration of action compared to short-term methods such as pills or condoms. Moreover, technological advancements are leading to the development of new and improved contraceptive options that offer better user experiences and fewer side effects. For instance, the advent of hormonal patches and vaginal rings provides more flexibility and ease of use, encouraging more individuals to consider these alternatives.

Contraceptive use is increasing worldwide, marking a positive shift in global reproductive health. Consumer preferences in the contraceptive market are also shifting towards products that offer additional health benefits beyond pregnancy prevention. For instance, some contraceptive pills are designed to alleviate menstrual-related issues such as heavy bleeding and severe cramps, making them more attractive to users. Furthermore, the rise of e-commerce platforms and telemedicine services is revolutionizing the way contraceptives are accessed and purchased. These digital channels provide greater privacy, convenience, and accessibility, particularly for individuals in remote or underserved areas. As a result, the contraceptive market is expanding to reach a broader audience, contributing to its sustained growth and development.

Select Competitors (Total 92 Featured) -

• Agile Therapeutics, Inc.
• Allergan plc
• Ansell Limited
• Bayer AG
• Church & Dwight Co., Inc.
• CooperSurgical Inc.
• Fuji Latex Co. Ltd.
• Janssen Pharmaceuticals, Inc.
• Karex Berhad
• Mankind Pharma Ltd.
• Okamoto Industries, Inc.
• Pfizer Inc.
• Piramal Enterprises Ltd.
• Reckitt Benckiser Group Plc.
• Sagami Rubber Industries Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Thai Nippon Rubber Industry Co., Ltd.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.